Akums Drugs Pharmaceuticals Ltd vs Bharat Immunological Biological Corporation Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Akums Drugs & Pharmaceuticals Ltd is ₹ 520.1 as of 18 May 15:30 . The P/E Ratio of Akums Drugs & Pharmaceuticals Ltd changed from 21.5 on March 2025 to 21.5 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 7469 crore on March 2025 to ₹ 7469 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Akums Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 1193 crore as compare to the Dec '25 revenue of ₹ 1193 crore. This represent the decline of -0.06% The revenue of Bharat Immunological & Biological Corporation Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Akums Drugs & Pharmaceuticals Ltd for the Mar '26 is ₹ 185.23 crore as compare to the Dec '25 ebitda of ₹ 162.96 crore. This represent the growth of 13.67% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Akums Drugs & Pharmaceuticals Ltd changed from ₹ 61.21 crore to ₹ 81.34 crore over 8 quarters. This represents a CAGR of 15.28% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Akums Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Akums Drugs & Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC. Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients.
Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services.
Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation.

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

FAQs for the comparison of Akums Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd

Which company has a larger market capitalization, Akums Drugs & Pharmaceuticals Ltd or Bharat Immunological & Biological Corporation Ltd?

Market cap of Akums Drugs & Pharmaceuticals Ltd is 8,186 Cr while Market cap of Bharat Immunological & Biological Corporation Ltd is 75 Cr

What are the key factors driving the stock performance of Akums Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd?

The stock performance of Akums Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Akums Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd?

As of May 18, 2026, the Akums Drugs & Pharmaceuticals Ltd stock price is INR ₹520.1. On the other hand, Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.47.

How do dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd compare?

To compare the dividend payouts of Akums Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.